Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Revenue (2016 - 2023)

Historic Revenue for Spyre Therapeutics (SYRE) over the last 7 years, with Q2 2023 value amounting to $688000.0.

  • Spyre Therapeutics' Revenue rose 1008.0% to $688000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $688000.0, marking a year-over-year decrease of 4094.42%. This contributed to the annual value of $886000.0 for FY2023, which is 6195.79% down from last year.
  • According to the latest figures from Q2 2023, Spyre Therapeutics' Revenue is $688000.0, which was up 1008.0% from $198000.0 recorded in Q1 2023.
  • Spyre Therapeutics' Revenue's 5-year high stood at $12.0 million during Q2 2021, with a 5-year trough of $168000.0 in Q4 2022.
  • Moreover, its 3-year median value for Revenue was $688000.0 (2023), whereas its average is $3.4 million.
  • In the last 5 years, Spyre Therapeutics' Revenue crashed by 9855.0% in 2022 and then skyrocketed by 1008.0% in 2023.
  • Quarter analysis of 3 years shows Spyre Therapeutics' Revenue stood at $3.6 million in 2021, then crashed by 95.39% to $168000.0 in 2022, then surged by 309.52% to $688000.0 in 2023.
  • Its last three reported values are $688000.0 in Q2 2023, $198000.0 for Q1 2023, and $168000.0 during Q4 2022.